Alzheimer CSF biomarkers in routine clinical setting

Acta Neurologica Scandinavica

Volumn 125, Issue 6, 2012, Pages 416-423

  Tabaraud, F ^a   Leman, J P ^a   Milor, A M ^a   Roussie, J M ^b   Barriere G ^b   Tartary, M ^b   Boutros Toni, F ^b   Rigaud, M ^b  

^a Clinique du Colombier   (France)

^b Astralab Clinical Laboratory   (France)

Author keywords

A 1 40 peptide; A 1 42 peptide; Alzheimer's disease; Innotest Amyloid Tau Index; P tau 181; T tau

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; THREONINE 181 HYPERPHOSPHORYLATED TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID TAU INDEX; ANALYTICAL PARAMETERS; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; TAU PROTEINS;

EID: 84860149586     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01592.x     Document Type: Article

References (36)

1. Blennow K, De Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403.
2. Morris JC, Roe CM, Xiong C et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-31.
3. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
4. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46.
5. Hort J, O'Brien JT, Gainotti G et al. On Behalf of the EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010;17:1236-48.
6. Dubois B, Feldman HH, Jacova C et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-27.
7. Petersen RC, Smith GE, Waring SC et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8.
8. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13.
9. Sunderland T, Linker G, Mirza N et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094-103.
10. Mitchell AJ. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 2009;80:966-75.
11. Hulstaert F, Blennow K, Ivanoiu A et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-62.
12. Andreasen N, Minthon L, Davidsson P et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-9.
13. Hampel H, Teipel SJ, Fuchsberger T et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004;9:705-10.
14. Ibach B, Binder H, Dragon M et al. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 2006;27:1202-11.
15. Vanderstichele H, De Vreese K, Blennow K et al. Analytical performance and clinical utility of the Innotest phospho-tau181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 2006;44:1472-80.
16. Parnetti L, Lanari A, Silvestrelli G et al. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Mech Ageing Dev 2006;127:129-32.
17. Lanari A, Parnetti L. Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting. ScientificWorldJournal 2009;9:961-6.
18. Henneman WJ, Vrenken H, Barnes J et al. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 2009;73:935-40.
19. Tapiola T, Alafuzoff I, Herukka SK et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-9.
20. Wallin AK, Blennow K, Zetterberg H et al. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010;74:1531-7.
21. Kester MI, Boelaarts L, Bouwman FH et al. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord 2010;29:491-7.
22. Clark CM, Xie S, Chittams J et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003;60:1696-702.
23. Buerger K, Ewers M, Pirttilä T et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006;129:3035-41.
24. Fagan AM, Mintun MA, Mach RH et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-9.
25. Ceravolo R, Borghetti D, Kiferle L et al. CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease. Brain Res Bull 2008;76:80-4.
26. Wiltfang J, Esselmann H, Bibl M et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem 2007;101:1053-9.
27. Neary D, Snowden JS, Gustafson L et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54.
28. McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-72.
29. Sjögren M, Vanderstichele H, Agren H et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93years of age: establishment of reference values. Clin Chem 2001;47:1776-81.
30. Hansson O, Zetterberg H, Buchhave P et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-34.
31. Nicolai I, Vernoux L, Pottel H et al. Analyse combinée des biomarqueurs protéiques du liquide céphalo-rachidien. Proceedings of IIemes Journées de la fédération des CM2R, Montpellier 2005.
32. Visser PJ, Verhey F, Knol DL et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009;8:619-27.
33. Welge V, Fiege O, Lewczuk P et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm 2009;116:203-12.
34. Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 2005;107:165-73.
35. Schneider JA, Arvanitakis Z, Bang W et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197-204.
36. Burack MA, Hartlein J, Flores HP et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010;74:77-84.